Featured Image
U.S. Service personnel receiving a COVID injectionU.S. Army

(The Dossier) – There are some wild headlines emerging on TV and in the corporate press about a U.S. Department of Defense-developed “super vaccine” for COVID-19, which is claimed to have the promise to work as a “pan-coronavirus” cure for any and all current and future variants.

Is the COVID-19 killer finally here? Your humble correspondent dug a little deeper into these claims.

The DOD’s Walter Reed Army Institute of Research (WRAIR) is doing a press tour for the preliminary results of a stage 1 trial for its Spike Ferritin Nanoparticle COVID-19 vaccine, or SpFN.

Defense One reports:

“Within weeks, scientists at the Walter Reed Army Institute of Research expect to announce that they have developed a vaccine that is effective against COVID-19 and all its variants, even Omicron, as well as from previous SARS-origin viruses that have killed millions of people worldwide.”

On December 16, the Army issued a press release about its nanoparticle COVID shot.

Kayvon Modjarrad, co-inventor of the vaccine and the U.S. Army lead for SpFN, said in a statement celebrating this development:

“Our strategy has been to develop a ‘pan-coronavirus’ vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species.”

Modjarrad added:

“This vaccine stands out in the COVID-19 vaccine landscape. The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection.”

The Army says that phase 1 human trials were completed at the beginning of this month, adding that their shots proved effective against the Omicron variant and “future strains.” It’s not clear how this Omicron claim is even possible, given that Omicron was first reportedly detected on November 24.

There are currently more than 60 nanoparticle-based COVID shots in pre clinical development, and 26 candidates have advanced into clinical trials.

Here’s what’s publicly know about the trial.

There’s 29 participants enrolled in the stage 1 human trials for the SpFN vaccine. All 29 individuals had to be deemed healthy, between the ages of 18-55, and having a BMI under 35 prior to being enrolled in the trial.

[95% of COVID-19 deaths occur in people who are over 50 years old. Additionally, the vast majority of people who have severe complications from COVID-19 are elderly and/or have several comorbidities. The most common underlying conditions for COVID-19 complications are all related to obesity. Therefore, the trial, while abiding by standard protocols, ruled out any participant who is realistically threatened by COVID-19.]

According to the trial information, the vaccine group is designed to have a 5 to 1 ratio to that of the placebo group. With only 29 of an expected 72 participants enrolled in phase 1 trials, this means our control group sample size is tiny – a probable control group of 5 people. Yes, 5 whole human beings.

The stories that are populating the media, and the Army’s hype of a pan-coronavirus, cure-all, is not only unwarranted, but deeply suspect.

Meanwhile, just one day before the Army celebrated preclinical studies on its COVID cure-all shots, Dr. Anthony Fauci and his colleagues in Government Health published a paper titled, “Universal Coronavirus Vaccines — An Urgent Need.”

Reprinted with permission from The Dossier


Commenting Guidelines
LifeSiteNews welcomes thoughtful, respectful comments that add useful information or insights. Demeaning, hostile or propagandistic comments, and streams not related to the storyline, will be removed.

LSN commenting is not for frequent personal blogging, on-going debates or theological or other disputes between commenters.

Multiple comments from one person under a story are discouraged (suggested maximum of three). Capitalized sentences or comments will be removed (Internet shouting).

LifeSiteNews gives priority to pro-life, pro-family commenters and reserves the right to edit or remove comments.

Comments under LifeSiteNews stories do not necessarily represent the views of LifeSiteNews.